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esponsibility of InstAbstract A rapid and sensitive LC–MS/MS method for the simultaneous quantitation of lamivudine,
zidovudine and nevirapine in human plasma using abacavir as internal standard has been developed and
validated. The analytes and IS were extracted from plasma by solid phase extraction using Oasis HLB
cartridges and separated on a Hypurity Advance C18 column using a mixture of acetonitrile:0.1% formic acid
(76:24, v/v) at a ﬂow rate of 0.8 mL/min. Detection involved an API-4000 LC–MS/MS with electrospray
ionization in the positive ion mode and multiple-reaction monitoring for analysis. The method was validated
according to FDA guidelines and shown to provide intra- and inter-day precision and accuracy within
acceptable limits in a run time of only 3.5 min. The method was successfully applied to a pharmacokinetic
study involving a single oral administration of a combination tablet to human male volunteers.
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Antiretroviral drugs are used to treat infections by retroviruses,
primarily the human immunodeﬁciency virus (HIV). The aim of
antiretroviral treatment is to maintain HIV at a low level in the
body. Since single drug therapy rapidly becomes ineffective due to
the development of HIV resistant strains, the new paradigm is to
combine two to four antiretroviral drugs in what is called highly
active antiretroviral therapy (HAART)1,2. The synergistic action
of different classes of antiretroviral drugs prolongs the survival of
HIV patients such that combination therapy is now considered
ﬁrst-line therapy.
Current treatment guidelines state that a combination
antiretroviral regimen should contain at least two nucleo-
side analog reverse transcriptase inhibitors (NRTIs) and
one non-nucleoside reverse transcriptase inhibitor (NNRTI)
in a ﬁxed dose combination3. One such combination
product is Lazid-N (Emcure Pharmaceuticals, Pune, India)
which is a combination of lamivudine, zidovudine and
nevirapine in a single pill. Lamivudine (20-deoxy-30-thiacy-
tidine) and zidovudine (30-azido-30-deoxythymidine) are
NRTIs whereas nevirapine (11-cyclopropyl-5,11-dihydro-4-
methyl-6H- dipyrido[3, 2-b: 20, 30-e]1,4 diazepin-6-one) is a
highly potent noncompetitive NNRTI. The combination is
considered to be one of the best choices for the treatment
of HIV.
According to the literatures, several LC–MS/MS4–10 methods
have been reported for the determination of lamivudine, zido-
vudine and nevirapine in biological samples either individually or
simultaneously with other drugs. However, only one LC–MS/
MS method11 has been reported for the simultaneous determina-
tion of the three drugs in human plasma but it analyses the three
drugs in combination with fourteen other antiretroviral drugs.
As expected, the method suffers from various deﬁciencies in
respect of the three drugs in question including the need for
complex sample preparation, gradient elution and polarity
switching. Thus the aim of the present study was to develop
and validate a speciﬁc, sensitive and high throughput LC–MS/
MS method for the simultaneous determination of lamivudine,
zidovudine and nevirapine in human plasma. The validated
method was applied to a clinical pharmacokinetic study invol-
ving oral administration of a combination of the three drugs to
healthy male volunteers.Figure 1 Chemical structures of lamivudine,2. Material and methods
2.1. Chemicals and reagents
Reference standards of lamivudine (99.7%), zidovudine
(99.1%), nevirapine (100.1%) and abacavir (99.2%, used as
internal standard, IS) were obtained from Aurobindo Phar-
maceuticals Ltd. (Hyderabad, India). Their chemical struc-
tures are presented in Fig. 1. Co-administration of Combivirs
tablet containing lamivudine 150 mg and zidovudine 300 mg
(Glaxo SmithKline, USA) and Viramunes tablet containing
Nevirapine 200 mg (Boehringer Ingelheim Pharmaceuticals,
Inc., USA). Water was prepared using a Milli Q water
puriﬁcation system from Millipore (Bangalore, India). Acet-
onitrile and methanol (HPLC grade) were purchased from J.T.
Baker (Phillipsburg, USA). Extra pure formic acid was
purchased from Fluka (Steinheim, Germany). Oasis HLB
cartridges were obtained from Waters (Massachusetts,
USA). Blank drug free human plasma was procured from
Deccan’s Pathological Laboratories (Hyderabad, India).2.2. Instrumentation and chromatographic conditions
Chromatographic separation was carried out on a Shimadzu
HPLC with a Hypurity advance C18 column (50 mm
4.6 mm, 5 mm; Thermo Scientiﬁc Ltd., Mumbai, India) and a
mobile phase consisting of acetonitrile:0.1% formic acid
(74:26, v/v) delivered at a ﬂow rate of 0.8 mL/min. The
injection volume was 5 mL. Quantitation was achieved in a
run time of 3.5 min by MS/MS detection in the positive ion
mode using an MDS Sciex API-4000 mass spectrometer
(Foster City, CA, USA) equipped with a TurboionsprayTM
interface at 600 1C and ion spray voltage set at 5500 V. Source
parameters viz. nebulizer gas (GS1), auxiliary gas (GS2),
curtain gas (CUR) and collision gas (CAD) were set at 35,
35, 20 and 6 psi, respectively. Compound parameters viz.
declustering potential (DP), collision energy (CE), entrance
potential (EP) and collision cell exit potential (CXP) were
respectively 36, 16, 10 and 6 V for lamivudine, 70, 44, 10 and
22 V for zidouvdine, 36, 11, 10 and 6 V for nevirapine and 36,
28, 10 and 6 V for IS. Detection was carried out by multiple-
reaction monitoring (MRM) of the transitions (precursor ionzidovudine, nevirapine and abacavir (IS).
Murali Krishna Matta et al.474to product ion) at m/z 230.3-112.1 for lamivudine, m/z
268.1-127.1 for zidouvdine, m/z 267.2-226.2 for nevirapine
and m/z 287.2-191.2 for IS. Quadrupoles Q1 and Q3 were set
on unit resolution. Analytical data were processed by Analyst
SoftwareTM (version 1.4.2). Fragmentation patterns were
similar to those previously reported for lamivudine12 zidovu-
dine12, nevirapine13 and IS14.2.3. Preparation of calibration standards and quality control
samples
Stock solutions (1 mg/mL) of lamivudine, zidovudine, nevirapine
and IS were prepared in methanol and diluted with 60:40 (v/v)
methanol:water to produce standard solutions. Nine mixed
calibration standards were then prepared by spiking blank K2-
EDTA plasma with appropriate volumes of the standard solu-
tions to give respective ﬁnal concentrations of 25, 50, 100, 301,
804, 1609, 2414, 3018 and 4024 ng/mL for lamivudine, 25, 50,
100, 301, 804, 1608, 2413, 3016 and 4022 ng/mL for zidovudine
and 81, 162, 255, 506, 1013, 2026, 3242, 4559 and 6079 ng/mL for
nevirapine. Four mixed quality control (QC) samples (LLOQ,Figure 2 Typical MRM chromatograms of lamivudine (left panel) an
spiked with IS, and (C) an LLOQ sample along with IS.LQQ, MQC and HQC) were prepared independently in the same
way with respective concentrations of 25, 75, 1913 and 3223 ng/
mL for lamivudine, 25, 75, 1910 and 3217 ng/mL for zidovudine
and 81, 243, 3037 and 5063 ng/mL for nevirapine. All validation
samples were stored at 70 1C until use.
2.4. Sample preparation
To an aliquot of human plasma (100 mL) was added 25 mL IS
working solution (500 ng/mL abacavir) and 100 mL 0.5 M potas-
sium phosphate buffer (pH 7.4) and the mixture vortexed for 10 s.
The mixture was then loaded onto a HLB cartridge (30 mg/mL)
pre-conditioned with 1.0 mL methanol followed by 1.0 mL water.
The cartridge was washed with 1.0 mL water followed by 1.0 mL
5% methanol in water after which analytes and IS were eluted
with 1.0 mL 0.5% formic acid in methanol. The eluate was
subsequently injected into the LC–MS/MS system.
2.5. Assay validation
Validation parameters viz. selectivity, speciﬁcity, matrix
effects, linearity, precision, accuracy, recovery, dilutiond IS (right panel) in (A) human blank plasma, (B) human plasma
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guidelines15. Selectivity was assessed by comparing the chro-
matograms of blank plasma samples from six different
individuals analyzed alone and after spiking at the respective
LLOQ concentrations. Matrix effects were checked by analysis
in triplicate of LQC and HQC samples prepared from six
different lots of plasma. Linearity was assessed by linear
weighted least squares regression of calibration curves con-
structed using the nine mixed calibration standards and
blank plasma samples. Intra- and inter-day precision and
accuracy were determined by analyzing six replicates of QC
samples on two different days and on four different days
respectively. Recoveries of analytes and IS were determined by
comparing peak areas of extracted QC samples (LQC, MQC
and HQC) with peak areas of non-extracted standards.
Recovery of IS was determined at a concentration of
500 ng/mL. Dilution integrity was assessed by analysis of six
replicates of a sample containing 1.5 times the maximum
calibration standard concentration diluted two- and four-fold
with blank plasma.
Stability was determined by comparing peak areas of
analytes with those of fresh samples for stock solutions atFigure 3 Typical MRM chromatograms of zidovudine (left panel) an
spiked with IS, and (C) an LLOQ sample along with IS.room temperature and under refrigerated conditions (2–8 1C)
and for prepared samples in the autosampler for 30 h. Stability
was also determined using LQC and HQC samples stored on
the bench for 10 h, on dry ice for 10 h, subjected to four
freeze–thaw cycles and at 70 1C for 60 days. In all cases six
replicates were analyzed. Samples were considered to be stable
if assay values were within the acceptable limits of accuracy
(85–115%) and precision (r15% RSD).2.6. Pharmacokinetic study
The protocol of a pharmacokinetic study in healthy male
subjects (n¼6) was approved by Hyderabad Independent
Ethics Committee (Hyderabad, India) and the volunteers
provided informed written consent. Blood samples were
collected in K2-EDTA Vacutainers (BD, Franklin, NJ, USA)
pre-dose and following oral administration of a combination
tablet containing lamivudine (150 mg), zidovudine (300 mg)
and nevirapine (200 mg) at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2,
2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24, 36, 48 and 72 h. Plasma
was collected after centrifugation at 3200 rpm for 10 min andd IS (right panel) in (A) human blank plasma, (B) human plasma
Figure 4 Typical MRM chromatograms of nevirapine (left panel) and IS (right panel) in (A) human blank plasma, (B) human plasma
spiked with IS, and (C) an LLOQ sample along with IS (C).
Table 1 Precision and accuracy for lamivudine, zidovudine and nevirapine in human plasma samples.
Analyte Concentration
added (ng/mL)
Intra-day (n¼12; 6 from each batch) Inter-day (n¼24; 6 from each batch)
Concentration found
(mean, ng/mL)
Precision
(%)
Accuracy
(%)
Concentration found
(mean, ng/mL)
Precision
(%)
Accuracy
(%)
Lamivudine 25.4 23.5 8.8 92.8 23.5 6.0 92.5
75.8 75.9 7.9 100.2 74.9 7.0 98.9
1913.9 1799.0 5.3 94.0 1798.9 4.8 94.0
3223.4 3182.9 3.1 98.8 3169.7 4.2 98.3
Zidovudine 25.3 28.2 2.6 111.2 27.6 3.4 109.1
75.6 78.8 8.1 104.2 79.4 7.8 105.0
1910.5 1858.2 6.6 97.3 1841.7 5.8 96.4
3217.6 3379.5 2.7 105.0 3326.6 4.1 103.4
Nevirapine 81.1 85.8 3.9 105.8 85.7 3.6 105.7
243.0 220.3 3.3 90.7 219.1 3.2 90.2
3037.8 2895.4 5.1 96.4 2821.3 4.5 92.9
5063.0 4883.2 2.0 96.5 4714.4 4.5 93.1
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MQC and HQC samples were assayed in triplicate. The
plasma concentration–time proﬁles of lamivudine, zidovudine
and nevirapine were analyzed by a non-compartmental
method using WinNonlin Version 5.1.3. Results and discussion
3.1. Method development
Detection using the positive ionization mode was found to
produce a better response than using the negative ionization
mode. Sample preparation using a simple solid-phase extrac-
tion (SPE) technique was found to provide high recoveries of
all analytes. In terms of chromatographic conditions, the
presence of a small amount of formic acid in the mobile
phase improved the detection of analytes and the Hypurity
advance C18 column gave good peak shapes and responses forTable 2 Stability of lamivudine, zidovudine and nevirapine in p
Analyte Stability test QC (nominal conc., ng/mL) Mean7
Lamivudine Autosamplera 75.8 76.47
3223.4 3313.77
Coolantb 75.8 75.37
3223.4 3289.07
Bench topc 75.8 65.77
3223.4 3332.17
FTd 75.8 71.97
3223.4 3067.47
Long-terme 75.8 70.37
3223.4 3046.47
Zidovudine Autosamplera 75.6 65.27
3217.6 3342.77
Coolantb 75.6 68.37
3217.6 3323.27
Bench topc 75.6 65.77
3217.6 3332.17
FTd 75.6 65.97
3217.6 3194.07
Long-terme 75.6 81.07
3217.6 3542.37
Nevirapine Autosamplera 243.0 233.57
5063.0 5023.67
Coolantb 243.0 232.27
5063.0 5000.17
Bench topc 243.0 233.37
5063.0 4992.47
FTd 243.0 226.37
5063.0 4746.37
Long-terme 243.0 217.57
5063.0 4599.97
aExtracted samples in autosampler for 30 h at 10 1C;
bOn dry ice for 10 h;
cAt room temperature for 10 h;
dFour freeze–thaw cycles;
eAt 70 1C for 60 days.all analytes and IS even at the LLOQs. Representative
chromatograms obtained from blank plasma and plasma
spiked with lamivudine, zidovudine and nevirapine at LLOQ
are presented in Figs. 2–4, respectively. The short retention
times of lamivudine, zidovudine, nevirapine and IS (1.13, 1.49,
1.56 and 0.99 min respectively) allowed a run time of only
3.5 min. The assay was free of interference at the retention
time of analytes and IS. Selectivity was also evaluated in the
presence of other commonly used anti-retroviral drugs such as
tenofovir, lopinavir, ritonavir, stavudine, indanavir and emtri-
citabine. Again no interference was observed at the retention
time of analytes and IS.3.2. Assay validation
3.2.1. Sensitivity
LLOQs of analytes were set at the lowest concentrations on
the standard curves. Precision and accuracy at the LLOQslasma samples (n¼6).
SD (ng/mL) Stability (% nominal conc.) Precision (% CV)
4.4 100.8 5.8
230.1 102.8 6.9
3.4 99.4 6.7
213.6 102.0 4.6
3.9 86.9 5.9
92.0 103.6 2.8
1.1 94.9 1.6
75.3 95.2 2.5
2.7 108 3.8
79.9 92.8 2.6
1.4 86.2 2.2
97.9 103.9 2.9
2.2 90.3 3.2
61.7 103.3 1.9
3.9 86.9 5.9
92.0 103.6 2.8
4.3 87.1 6.5
126.7 99.3 4.0
4.9 107.1 6.0
117.0 110.1 3.3
6.0 96.1 2.6
47.5 99.2 1.0
1.7 95.6 0.7
95.7 98.8 1.9
4.2 96.0 1.8
42.9 98.6 0.9
2.3 93.1 1.0
82.1 93.7 1.7
11.5 89.5 5.3
141.8 90.9 3.1
Murali Krishna Matta et al.478were respectively 2.50% and 94.80% for lamivudine, 4.64%
and 92.49% for zidovudine, and 1.32% and 90.19% for
nevirapine.Figure 5 Mean plasma concentration–time proﬁles of (A) lami-
vudine, (B) zidovudine and (C) nevirapine in human plasma
following oral administration of a combination tablet containing
lamivudine (150 mg), zidovudine (300 mg) and nevirapine
(200 mg) to healthy male volunteers (data are means7SD, n¼6).3.2.2. Matrix effects
No signiﬁcant matrix effects were observed in the six batches
of LQC and HQC samples. Accuracy for analytes in LQC and
HQC samples were respectively; 93.89% and 95.62% for
lamivudine, 95.58% and 101.33% for zidovudine and 94.64%
and 94.39% for nevirapine.
3.2.3. Linearity
Calibration curves were found to be linear for all three
analytes over their respective concentration ranges. After
comparing weighting by 1/x and 1/x2, a regression equation
of analyte to IS concentration with a weighting factor of 1/x2
was found to produce the best ﬁt for all analytes (mean
correlation coefﬁcient Z0.99).
3.2.4. Precision and accuracy
As shown in Table 1, the intra- and inter-day precision for all
analytes was in the range 85–115% with accuracy of715% at
LQC, MQC and HQC concentrations. Precision and accuracy
at the LLOQs were in the range 80–120% and 720%,
respectively.
3.2.5. Extraction efﬁciency
Solid phase extraction using HLB cartridges was shown to be
robust, provide clean samples and give good and reproducible
recoveries of all analytes and IS. The mean overall recoveries
across QC levels (with precision) were 83.5775.05% (2.45–
4.84%) for lamivudine, 92.2675.01% (2.55–7.19%) for zido-
vudine and 88.3775.08% (1.82–2.73%) for nevirapine. The
recovery of IS was 78.9470.72% with precision of 2.82%.
3.2.6. Dilution integrity
The upper concentration limits were shown to be extendable
up to 6000 ng/mL for lamivudine and zidovudine and up to
9000 ng/mL for nevirapine by dilution with blank plasma. The
mean back-calculated concentrations for half and quarter
dilutions were 85–115% of their nominal values with coefﬁ-
cients of variation (%CV) of o8% for all three analytes.
3.2.7. Stability studies
In the different stability experiments, the concentrations of
analytes were found to remain at 715% of the predicted
concentrations (Table 2) indicting no stability issues for any of
the analytes.
3.3. Application to a pharmacokinetic study
Mean plasma concentration vs. time proﬁles of lamivudine,
zidovudine and nevirapine are shown in Fig. 5 with corre-
sponding pharmacokinetic parameters listed in Table 3. The
values are in close proximity to those previously reported16.
3.4. Incurred sample re-analysis
The FDA now requires that incurred sample reanalysis (ISR)
of dosed subject samples be carried out to demonstrate assay
reproducibility17. ISR was performed using two plasma
samples from each subject and re-assayed in a separate batch
run. The differences in concentrations between the ISR and
the initial values for all tested samples were o15% (Table 4)
indicating good reproducibility of the method.
Table 3 Pharmacokinetic parameters of lamivudine, zidovudine and nevirapine (data are Mean7SD, n¼6).
Parameter Lamivudine Zidovudine Nevirapine
Cmax (ng/mL) 1195.27361.2 2020.77795.7 2472.47558.1
Tmax (h) 1.5670.77 0.5670.25 6.3378.77
AUC0t (ng  h/mL) 6525.171931.1 2966.37410.3 111773.3717771.5
AUC0N(ng  h/mL) 6929.072003.1 3051.97413.4 203579.6733637.3
t1/2 (h) 4.7073.35 1.4870.20 61.68716.09
Ke (h1) 0.1970.08 0.4870.07 0.0170.00
Vd (L) 0.1470.07 0.2170.02 0.0970.02
CL (L/h/kg) 0.0270.01 0.1070.01 0.0070.00
Table 4 Incurred samples re-analysis data of lamivudine, zidovudine and nevirapine.
Sample Lamivudine Zidovudine Nevirapine
Initial conc.
(ng/mL)
Re-assay conc.
(ng/mL)
Differencea
(%)
Initial conc.
(ng/mL)
Re-assay
conc.
(ng/mL)
Differencea
(%)
Initial conc.
(ng/mL)
Re-assay
conc.
(ng/mL)
Differencea
(%)
1 720.1 745.2 3.4 645.8 631.5 2.2 2621.2 2354.1 10.7
2 443.2 430.2 3.0 68.9 60.3 13.4 2515.6 2425.2 3.7
3 767.9 750.7 2.3 451.7 470.3 4.0 2338.9 2562.1 9.1
4 318.6 300.1 6.0 68.8 65.2 5.3 1939.5 2000.2 3.1
5 1135.5 1115.3 1.8 735.5 726.3 1.3 2247.6 2216.9 1.4
6 717.0 725.3 1.1 123.3 115.5 6.5 3267.7 3001.5 8.5
7 1268.3 1398.2 9.7 740.8 751.5 1.4 2312.7 2384.2 3.0
8 647.5 672.1 3.7 64.7 58.2 10.5 1855.9 1902.4 2.5
9 973.4 985.2 1.2 686.7 675.5 1.6 1259.2 1246.7 1.0
10 406.7 398.2 2.1 82.8 88.5 6.6 1226.1 1219.5 0.5
11 1190.2 1155.8 2.9 472.9 455.3 3.8 2157.9 2312.6 6.9
12 568.3 540.8 5.0 96.4 90.1 6.8 1791.1 1897.2 5.8
aDifference (%)¼ [(Initial conc.Re-assay conc.)/Average conc.] 100%; Average conc.¼ (Initial conc.Re-assay conc.)/2.
LC-MS/MS quantitation of lamivudine, zidovudine and nevirapine 4794. Conclusions
This paper describes for the ﬁrst time an LC–MS/MS method
for the simultaneous determination of lamivudine, zidovudine
and nevirapine in human plasma. The proposed method
involves simple sample preparation and provides adequate
sensitivity in a run time of only 3.5 min. The method was
successfully applied to a human pharmacokinetic study and
has the potential to be useful for bioequivalence studies and
routine therapeutic drug monitoring.
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